Intellia Therapeutics, Inc. to Post Q2 2024 Earnings of ($1.14) Per Share, Leerink Partnrs Forecasts (NASDAQ:NTLA)

Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report) – Stock analysts at Leerink Partnrs issued their Q2 2024 earnings per share estimates for Intellia Therapeutics in a research note issued to investors on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($1.14) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.45) per share.

Several other equities research analysts also recently commented on the company. Royal Bank of Canada dropped their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, November 10th. The Goldman Sachs Group dropped their target price on Intellia Therapeutics from $157.00 to $136.00 and set a “buy” rating on the stock in a report on Friday, November 10th. BMO Capital Markets dropped their target price on Intellia Therapeutics from $64.00 to $62.00 and set an “outperform” rating on the stock in a report on Friday, November 10th. Oppenheimer dropped their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Monday, November 13th. Finally, Morgan Stanley dropped their target price on Intellia Therapeutics from $90.00 to $85.00 and set an “overweight” rating on the stock in a report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.47.

Read Our Latest Stock Analysis on Intellia Therapeutics

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $25.74 on Thursday. Intellia Therapeutics has a twelve month low of $22.67 and a twelve month high of $47.48. The stock’s 50 day moving average is $29.39 and its 200 day moving average is $33.40.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.38) earnings per share for the quarter, beating the consensus estimate of ($1.52) by $0.14. Intellia Therapeutics had a negative return on equity of 40.49% and a negative net margin of 893.34%. The company had revenue of $11.99 million for the quarter, compared to analyst estimates of $12.45 million. During the same period in the previous year, the company posted ($1.49) earnings per share. The firm’s revenue was down 9.6% on a year-over-year basis.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Sandia Investment Management LP bought a new position in shares of Intellia Therapeutics in the fourth quarter worth about $35,000. Jefferies Financial Group Inc. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth about $38,000. ICA Group Wealth Management LLC bought a new position in shares of Intellia Therapeutics in the fourth quarter worth about $62,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after acquiring an additional 1,108 shares during the period. Finally, Penserra Capital Management LLC bought a new position in shares of Intellia Therapeutics in the first quarter worth about $97,000. Hedge funds and other institutional investors own 87.72% of the company’s stock.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 19,223 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $29.46, for a total transaction of $566,309.58. Following the completion of the sale, the chief executive officer now owns 846,486 shares in the company, valued at $24,937,477.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Intellia Therapeutics news, CEO John M. Leonard sold 19,223 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $29.46, for a total value of $566,309.58. Following the completion of the sale, the chief executive officer now owns 846,486 shares in the company, valued at $24,937,477.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Glenn Goddard sold 5,365 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $29.46, for a total value of $158,052.90. Following the completion of the sale, the chief financial officer now owns 40,585 shares of the company’s stock, valued at approximately $1,195,634.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,971 shares of company stock worth $968,510. 3.00% of the stock is owned by insiders.

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.

Recommended Stories

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.